secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2021-09-09T23:59:59+00:00
Accession:  0000950170-21-001738
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q2 revenue $4.9M (+81% YoY); net loss $(13.5)M; raises ~$120M in July IPO
--------------------------------------------------------------------------------

- Revenue $4.9M (+81% YoY); sold 25 LDDs and 1,825 LALs during Q2.
- Net loss $(13.5)M ($(3.28)/share basic); adjusted net loss $(13.3)M ($(3.24)/share).
- Gross loss $(0.8)M due to $1.7M inventory reserve for updated LAL with ActivShield.
- Completed IPO in July 2021 raising ~$120M net proceeds; cash & equivalents $61.7M at June 30.
- FDA approval and launch of LAL with ActivShield technology; new VP of U.S. Sales appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017021001738/0000950170-21-001738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017021001738/rxst-20210909.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer